Skip to content

Study · Not a test of the peptide alone · 2014

2 results

[Effect of peptide bioregulator and cobalt ions on the activity of NORs and associations of acrocentric chromosomes in lymphocytes of patients with hypertrophic cardiomyopathy and their relatives].

The source lists no authors.

Georgian medical news1 Sept 2014

PMID25341254 (opens in a new tab)PepBankPUB-25341254
Publisher pageAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Livagen (KEDA) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Livagen (KEDA).

  1. 01LabNot a test of Livagen (KEDA) aloneIn vitro (cells)Mechanism

    In lymphocytes from HCM patients and relatives, combined Livagen and cobalt increased the frequency of large-sized scoring 2 NORs.

    In plain wordsIn lab tests with HCM and relative lymphocytes, Livagen with cobalt increased the frequency of large nucleolar organizer regions.

    Peptide
    Livagen (KEDA)
    Outcome
    IncreaseLarge-sized scoring 2 NOR frequency
    Study

    humann: not reported in source

    Lymphocytes from HCM patients and their relatives
    Outcome group
    Genome stability · Whole body

    Source sentences

    Summary
    It is shown that combined action of Livagen and cobalt ions increases the frequency of large-sized scoring 2 NORs in both, patients and their relatives.
    1 context sentence
    Summary · context
    The influence of peptide bioregulator - Livagen (Lys-Glu-Asp-Ala) separately and combined with cobalt ions, on the activity of nucleolar organizer regions (NORs) and frequency of associations of acrocentric chromosomes in lymphocytes from patients with hypertrophic cardiomyopathy (HCM) and their rel…

    In this study, Livagen (KEDA) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Livagen (KEDA).

  2. 02LabNot a test of Livagen (KEDA) aloneIn vitro (cells)Mechanism

    In lymphocytes from HCM patients and relatives, the studied compounds increased acrocentric chromosome association, with Livagen and cobalt more effective.

    In plain wordsIn lab tests with HCM and relative lymphocytes, the studied compounds increased chromosome association, with Livagen and cobalt more effective.

    Peptide
    Livagen (KEDA)
    Outcome
    IncreaseAcrocentric chromosome association frequency
    Study

    humann: not reported in source

    Lymphocytes from HCM patients and their relatives
    Outcome group
    Genome stability · Whole body

    Source sentences

    Summary
    Significant was also the influence of the studied compounds on associative activity of acrocsentric chromosomes that was expressed in sharp increase of this indicator in both studied groups. In this case more effective was the action of Livagen and cobalt ions.
    1 context sentence
    Summary · context
    The influence of peptide bioregulator - Livagen (Lys-Glu-Asp-Ala) separately and combined with cobalt ions, on the activity of nucleolar organizer regions (NORs) and frequency of associations of acrocentric chromosomes in lymphocytes from patients with hypertrophic cardiomyopathy (HCM) and their rel…

    In this study, Livagen (KEDA) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Livagen (KEDA).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 17:05 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.